Uncategorized
Lifitegrast appears safe, well-tolerated in dry eye patients
SAN DIEGO – A new treatment for dry eye disease showed a high safety profile compared with placebo, according to a study presented here.At the World Cornea Congress, Eric D. Donnenfeld, MD, reviewed results of the SONATA study, a 1-year phase 3 multicenter, randomized, placebo-controlled clinical trial examining lifitegrast ophthalmic solution 5% (Shire) in patients with dry eye.